Eledon Pharmaceuticals
ELDN
33 hedge funds and large institutions have $12.7M invested in Eledon Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
21.96% more ownership
Funds ownership: 45.35% → 67.31% (+22%)
10% more funds holding
Funds holding: 30 → 33 (+3)
14% less capital invested
Capital invested by funds: $14.7M → $12.7M (-$2.02M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $12K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.17M |
| 2 |
AC
Armistice Capital
New York
|
+$3.84M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$570K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$105K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.87M |
| 2 |
BlackRock
New York
|
-$50.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$48.1K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$42.4K |
| 5 |
SFG
SVB Financial Group
Dallas,
Texas
|
-$18.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $15.7K | +$10.8K | +5,199 | +83% |
|
27
Two Sigma Investments
New York
| $14.5K | -$14.6K | -7,000 | -40% |
|
|
28
Citadel Advisors
Miami,
Florida
| $10.6K | -$48.1K | -23,070 | -75% |
|
29
Group One Trading
Chicago,
Illinois
| $8.11K | +$11.1K | +5,318 | +886% |
|
30
Morgan Stanley
New York
| $2.95K | +$4.49K | +2,155 | New |
|
31
Wells Fargo
San Francisco,
California
| $200 | +$125 | +60 | +70% |
|
32
UBS Group
Zurich,
Switzerland
| $44 | -$884 | -424 | -93% |
|
|
CAM
33
Cormorant Asset Management
Boston,
Massachusetts
| – | -$2.87M | -1,217,882 | Closed |
|
|
34
Dimensional Fund Advisors
Austin,
Texas
| – | -$42.4K | -17,954 | Closed |
|
|
AAS
35
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$2.27K | -1,000 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | +$315 | +151 | +219% |
|
ELDN Hedge Fund Activity: Q2 2023 in Review
33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2023, worth a combined $12.7M — down 14% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ELDN positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.17M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.87M sold.
- 33 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2023, up from 30 in Q1 2023.
- Funds reported $12.7M of Eledon Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q2 2023 and 3 closed out, a net change of +3 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2023 was BVF Inc, an estimated $4.17M added.
- The largest Eledon Pharmaceuticals seller in Q2 2023 was Cormorant Asset Management, an estimated $2.87M sold.
Based on aggregated 13F filings for Q2 2023.